COPD Assessment Test
Also known as: CAT, COPD Assessment Test, COPD Assessment Tool
The COPD Assessment Test (CAT) is a simple, rapid, patient-centered measure of COPD symptom burden and functional impact. Developed by Paul Jones and colleagues in 2009, this 8-item questionnaire captures how COPD affects cough, sputum, chest tightness, breathing difficulty, activity limitation, confidence, sleep, and energy. It is used worldwide in clinical practice to guide disease management decisions and as a primary outcome measure in COPD clinical trials.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The CAT is indicated for assessing symptom burden in patients with confirmed COPD across disease stages (GOLD Groups A-D). Use cases include baseline assessment to quantify symptom severity and guide treatment initiation, monitoring during treatment to track response and inform medication adjustments, case-finding in primary care (as part of case-finding in at-risk populations), outcome assessment in clinical trials as a primary or co-primary endpoint, and health economic analyses. The CAT is particularly valuable for patients with discordance between spirometry and symptoms, as it captures symptom-driven impairment. It is less suitable for acute exacerbations (use acute symptom scales) or for non-COPD patients.
Strengths & limitations
- Exceptional brevity—only 8 items, 2-3 minute completion, compatible with routine clinical workflow in primary care and respiratory clinics
- Strong psychometric properties—extensively validated in COPD populations worldwide with good internal consistency (Cronbach's α 0.70-0.90), reproducibility (ICC > 0.75), and responsiveness to treatment and disease progression
- Patient-centered—developed directly from COPD patient interviews and qualitative research, capturing symptoms and impacts patients identify as important
- Multidimensional coverage—addresses cough, sputum, chest tightness, dyspnea, activity limitation, psychological confidence, sleep, and energy, reflecting COPD's systemic effects
- Free and globally accessible—unrestricted access for clinical and research use; available in 40+ languages via official channels
- Guides clinical decision-making—CAT scores directly inform COPD treatment escalation, leading to improved patient-centered management
- Symptom-based only—does not measure objective lung function (FEV1) or exacerbation history; spirometry and exacerbation count must be assessed separately for complete COPD risk stratification
- Limited discriminant validity for COPD-specific complications—does not distinguish between causes of symptoms (e.g., dyspnea from pure airflow obstruction vs. dyspnea from comorbid heart failure) or assess other complications (pulmonary hypertension, cachexia)
- Does not predict mortality—CAT score correlates modestly with FEV1 (r = 0.40-0.60) and future exacerbation risk; COPD mortality is influenced by factors beyond CAT (e.g., FEV1, exacerbation frequency, age, comorbidity). Use CAT alongside exacerbation history and FEV1 for complete risk assessment (GOLD ABCD classification).
- Potential response bias—patients may under-report symptoms if they fear medication withdrawal or dismissal of concerns; conversely, they may over-report if they seek escalation in treatments
- Assumes stable disease—rapid symptom fluctuations (acute exacerbation) may produce variable CAT scores not reflecting baseline burden; assess during stable disease when possible
Frequently asked
A patient has CAT 8 (low) but FEV1 35% (severe COPD). Which is correct?
Both are correct but reflect different aspects. FEV1 is objective lung function; CAT is subjective symptom burden. This patient has severe airflow obstruction but exceptional symptom control, likely due to excellent medication management, good exercise tolerance, or psychological adaptation. GOLD classification (Group B or C depending on exacerbation history) guides treatment. No escalation is indicated if the patient is functionally stable; however, monitor closely for exacerbations or declining FEV1, which may signal changing COPD phenotype.
What does a CAT change of 4 points mean clinically?
A 4-point change (e.g., CAT 18 to 14) is the minimum clinically important difference and indicates a meaningful shift in perceived symptom burden. Whether improvement or worsening, a 4-point change warrants clinical attention: improvement may validate a treatment change; worsening may prompt assessment for exacerbations, medication non-adherence, or new comorbidities.
Should I use CAT or mMRC for COPD assessment?
Both have value. CAT is multidimensional (covers cough, sputum, energy, sleep, confidence, not just dyspnea) and easier for patients with limited literacy. mMRC (Modified Medical Research Council) is a simple dyspnea scale (0-4 grades) focused on exertional breathlessness. GOLD guidelines accept either for risk stratification; use CAT if patient-centered comprehensive assessment is desired, or mMRC if rapid dyspnea grading suffices. Some clinics use both for complementary information.
Is CAT appropriate in ACOS (Asthma-COPD Overlap)?
Yes. CAT measures symptom burden across respiratory disease, making it valid in ACOS. However, in ACOS, cough and sputum items may reflect asthmatic airway inflammation rather than pure COPD; add asthma control measures (ACT—Asthma Control Test) for complete assessment. Treatment in ACOS typically targets both asthma and COPD pathology, so tracking both CAT and ACT monitors whole disease burden.
Sources
- Jones, P. W., Harding, G., Berry, P., Wiklund, I., Chen, W. H., & Kline Leidy, N. (2009). Development and first validation of the COPD Assessment Test. European Respiratory Journal, 34(3), 648-654. DOI: 10.1183/09031936.00102509 ↗
- Dodd, J. W., Hogg, L., Nolan, J., Jeffries, C., Grant, E., Lord, V. M., ... & Hopkinson, N. S. (2012). The COPD assessment test (CAT): Response to pulmonary rehabilitation. A multicentre, prospective study. Thorax, 66(5), 425-429. DOI: 10.1136/thx.2010.156372 ↗
- Tinkelman, D., White, B., & Murray, S. (2009). Tracking COPD patient outcomes with COPD Assessment Test (CAT): A validation study. Journal of COPD F, 6(1), 1-6. link ↗
How to cite this page
ScholarGate. (2026, June 3). COPD Assessment Test. ScholarGate. https://scholargate.app/en/health-outcomes/copd-assessment-test
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- ACTHealth Outcomes↔ compare
- CHQHealth Outcomes↔ compare
- DQOLHealth Outcomes↔ compare
- EORTC QLQ-C30Health Outcomes↔ compare